Company Encyclopedia
View More
name
TRANSTHERA-B
02617.HK
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc.
1.300 T
02617.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TRANSTHERA's core product, Tiengoti, publishes exploratory clinical results

    TRANSTHERA announced that the exploratory Phase 2 results of its core product Tiengotine for cholangiocarcinoma conducted in the United States were published in The Lancet, Gastroenterology and Hepatology. The study shows that Tiengotine can overcome the resistance of FGFR2 fusion-positive cholangiocarcinoma patients to FGFR inhibitors and demonstrates antitumor activity in other patients with FGFR gene alterations

    AASTOCKS·
    HK
    02617
    +2.93%
    AASTOCKS·
    HK
    02617
    +2.93%

    Top 10 HK Stock Gainers (12.17)

    YOFC(06869) rose 21.21%, with a trading turnover 3.1 Billion HKD, and a year-to-date rose 290.1%. TRANSTHERA-B(02617) rose 17.41%, with a trading turnover 389.9 Million HKD, and a year-to-date rose 1202.7%. DRINDA(02865) rose 11.91%, with a trading turnover 100.8 Million HKD, and a year-to-date fell 19.4%.

    Top Gainers & Losers·
    HK
    06869
    +11.21%
    HK
    02617
    +2.93%
    HK
    02865
    -1.64%
    Top Gainers & Losers·
    HK
    06869
    +11.21%
    HK
    02617
    +2.93%
    HK
    02865
    -1.64%

    Hong Kong stock market closing | Hang Seng Index rose 0.92%, technology and consumer sectors strengthened, YOFC surged 21.21%

    The Hong Kong stock market closed today with all three major indices rising simultaneously, with the Hang Seng Index, Hang Seng Tech Index, and the National Enterprises Index all recording an increase of nearly 1%. The technology consumption sectors, such as internet content and information, performed remarkably well, with leading companies like Tencent Holdings seeing gains, and the technology sector once again attracting market funds. Retail sales maintained a year-on-year growth of 5.3%, signaling a clear recovery in consumption and boosting the market's bullish sentiment. Stocks like YOFC surged significantly, with hot funds focusing on high-elasticity targets. Overall market sentiment is positive, with structural funds flowing into technology and consumption sectors

    Market Heartbeat·
    HK
    02617
    +2.93%
    Market Heartbeat·
    HK
    02617
    +2.93%

    Hong Kong stock movement: TRANSTHERA-B rose 16.52%, benefiting from both clinical results of Tiengatinib and FDA certification

    TRANSTHERA-B rose 16.52%; Innovent Biologics fell 0.31%, with a transaction volume of HKD 507 million; 3SBio rose 0.62%, with a transaction volume of HKD 400 million; BeiGene rose 0.83%, with a transaction volume of HKD 363 million; CanSino Biologics fell 0.17%, with a market capitalization of HKD 107.5 billion

    HK Stock Movers Tracker·
    HK
    02617
    +2.93%
    HK Stock Movers Tracker·
    HK
    02617
    +2.93%

    Hong Kong stock market intraday | The Hang Seng Index rose 0.7% intraday, YOFC rose 19%, concept stocks strengthened

    The three major indices of the Hong Kong stock market fluctuated upward during the trading session, with the Hang Seng Index, Hang Seng Tech Index, and the National Enterprises Index all recording gains, but overall still operating below the phase high points. Funds continued to flow into popular concept sectors, with leading stocks like YOFC showing strong performance during the session, boosting market sentiment. The recovery in retail sales data and the improvement in consumer confidence stimulated optimistic sentiment among investors. Transactions in internet and financial blue chips were active, indicating that funds are focusing on leading targets. The short-term market structure and the rotation of the consumer sector are worth continuous attention

    Market Heartbeat·
    HK
    02617
    +2.93%
    Market Heartbeat·
    HK
    02617
    +2.93%
    © 2025 Longbridge｜Disclaimer